WA-ECHODYNE
Echodyne , the radar platform company, announced today the newest addition to its market-leading portfolio of radars - EchoShield. Designed from the ground-up to set a new price-performance standard for mid-range radars, EchoShield is an advanced software-defined multi-mission radar for a wide variety of commercial, defense, and government use cases.
EchoShield’s development has been informed by hundreds of customers and applications across multiple industries. The radar’s architecture builds upon the field-proven success of Echodyne’s proprietary metamaterials electronically scanned array (MESA®) radars that are in use across a wide range of applications, such as counter-UAS, border and base security, force protection, critical infrastructure security, intelligence, surveillance, and reconnaissance, UAV detect and avoid, and autonomous ground vehicles.
A pulse-Doppler cognitive 4D radar, EchoShield combines ultra-precise electronically scanned array (ESA) beamforming and real-time dynamic waveform synthesis to deliver sub-degree tracking accuracy on hundreds of objects across a broad 3D field of view. EchoShield’s cognitive search capabilities integrate onboard or offboard data stores to adapt and direct radar resources when and where required in order to deliver the right data and detail at the right time. Whether using the radar’s significant onboard processing capabilities or ingesting data-rich range-doppler spectrograms into offboard compute, EchoShield’s SDK enables deep integration and multi-sensor fusion.
EchoShield is designed to be software-optimized to mission profiles that align powerful dynamic radar resources with unique customer requirements to deliver superior radar performance. Based on market demand, the initial software release prioritizes a counter-UAS mission and excels at detecting, tracking, and classifying any uncrewed aircraft, including low slow and small drones even in dense urban environments. Further releases will match radar resources with customer demand in dozens of applications and markets.
“Radar is a fundamental sensor for a wide range of commercial and government applications, but achieving high performance at reasonable cost, size, weight and power (C-SWaP) has always been a challenge,” said Eben Frankenberg, CEO of Echodyne. “Our customers have challenged us with certain radar performance attributes and EchoShield has been designed to meet these demanding requirements. Our customers are lining up for first units and already discussing production volume, so we’re very pleased with the market reception.”
EchoShield is designed to operate in the Ku band, with radiolocation service at 15.7-16.6 GHz and radionavigation at 15.4-15.7 GHz, and is commercially exportable. Its features include:
- 130° azimuth x 90° elevation field of regard (fully customizable)
- 0.5° tracking accuracy in azimuth and elevation, with very low track splitting/dropping
- Powerful UAV classification with low false-alarms and near-zero false-negatives
- Cognitive search capabilities integrate onboard or offboard data
-
Average tracking ranges for counter-UAS mission:
- Group 1 (-20 to -10 dBsm): 2.7 to 4.8 km
- Group 2 (-10 to -5 dBsm): 4.8 to 6.4 km
- Group 3 (-5 to 5 dBsm): 6.4 to 11.4 km
“Our breakthrough Metamaterial-ESA technology unlocks a level of beamforming previously only available with large ultra-expensive AESA’s with hundreds of channels,” said Tom Driscoll, CTO of Echodyne. “EchoShield combines this precise beamforming with modern fully-adaptive cognitive-radar approaches and intelligent control software, and the result is a radar with best-in-class detection, tracking, and classification performance.”
For additional details and technical specifications, please visit our website at echodyne.com .
This device has not been authorized as required by the rules of the Federal Communications Commission. This device is not, and may not be, offered for sale or lease, or sold or leased, until authorization is obtained.
About Echodyne
Echodyne , the radar platform company, designs and delivers high-performance compact, solid-state, patent-protected MESA® radars. Ideally suited for defense, security, machine perception, and autonomy, Echodyne’s commercially priced electronically scanned array radars are used by defense and government agencies, autonomous developers, and security integrators for counter-UAS, borders and perimeter security, critical infrastructure protection, unmanned aerial vehicles, and autonomous vehicles. Privately held, the company is based in Kirkland, Washington, and is backed by Bill Gates, NEA, Madrona Venture Group, Vulcan Capital, Vanedge Capital, and Lux Capital among others. For more information, please visit: Echodyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom